CMRX Real Time Stock Quote - Get Chimerix, Inc. Common Stock (CMRX) last sale data in real-time at NASDAQ.com. Breaking things down more, CMRX is a member of the Medical - Products industry, which includes 86 individual companies and currently sits at #102 in the Zacks Industry Rank. On average, this group has gained an average of 0.42% so far this year, meaning that CMRX is performing better in terms of year-to-date returns. Stock quote for Chimerix, Inc. Common Stock Common Stock (CMRX) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq.

View Grupo Aval Acciones y Valores S.A. AVAL investment & stock information. Get the latest Grupo Aval Acciones y Valores S.A. AVAL detailed stock quotes,  View Banco Latinoamericano de Comercio Exterior, S.A. BLX investment & stock information. Get the latest Banco Latinoamericano de Comercio Exterior, S.A.  View Deere & Company DE investment & stock information. Get the latest Deere & Company DE detailed stock quotes, stock data, Real-Time ECN, charts, stats  Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. Gain free stock research access to stock picks, stock 

CMRX: Chimerix, Inc. equity research. Get the latest equity research information from Zacks Investment Research.

Chimerix Inc (NASDAQ:CMRX) was down 13.6% during trading on Tuesday . The stock traded as low as $2.01 and last traded at $2.03, approximately 602,327 shares traded Wall Street expects a year-over-year increase in earnings on higher revenues when Chimerix (CMRX) reports results for the quarter ended March 2019. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. Is Chimerix Inc (CMRX) A Good Stock To Buy? Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). 11/8/2018 · DURHAM, N.C. (AP) _ Chimerix Inc. (CMRX) on Thursday reported a loss of $16.1 million in its third quarter. The Durham, North Carolina-based company said it had a loss of 33 cents per share. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 42 cents per share. View detailed financial information, real-time news, videos, quotes and analysis on Chimerix Inc. (NASDAQ:CMRX). Explore commentary on Chimerix Inc. and hear what the What's going on at Chimerix (NASDAQ:CMRX)? View breaking news headlines for CMRX stock from trusted media outlets at MarketBeat. CMRX | Complete Chimerix Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

What's going on at Chimerix (NASDAQ:CMRX)? View breaking news headlines for CMRX stock from trusted media outlets at MarketBeat.

12/10/2019 · Results from a Phase 1 clinical trial evaluating Chimerix's (CMRX-20.6%) dociparstat sodium (DSTAT) in patients with refractory myelodysplastic syndromes 11/5/2019 · Chimerix (CMRX): Q3 EPS of -$1.26 may not be comparable to consensus of -$0.21. Revenue of $1.96M (+429.7% Y/Y) beats by $1.06M. Press Release CMRX: Get the latest Chimerix stock price and detailed information including CMRX news, historical charts and realtime prices.

Chimerix Inc. company facts, information and stock details by MarketWatch. View cmrx business summary and other industry information.

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. Gain free stock research access to stock picks, stock  DE: Deere & Company Detailed Estimate. Get the latest Detailed Estimate from Zacks Investment Research. View Chimerix, Inc. CMRX investment & stock information. Get the latest Chimerix, Inc. CMRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. CMRX: Chimerix, Inc. Detailed Estimate. Get the latest Detailed Estimate from Zacks Investment Research.

11/5/2019 · Chimerix (CMRX): Q3 EPS of -$1.26 may not be comparable to consensus of -$0.21. Revenue of $1.96M (+429.7% Y/Y) beats by $1.06M. Press Release

The Zacks Scorecard is a complimentary set of indicators to use alongside the Zacks Rank. It allows the investor to better focus on the stocks that are the best fit for his or her personal investment style. We produce five unique ratings, including the Zacks Style Score, which combines the individual style scores into 1 rating: Should I buy Chimerix, Inc. (CMRX)? Use the Zacks Rank and Style Scores to find out is CMRX is right for your portfolio. 11/8/2019 · Chimerix (NASDAQ:CMRX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday, Zacks.com reports. The firm currently has a $1.75 target price on the biopharmaceutical company’s stock. CMRX: Chimerix, Inc. broker recommendation chart. Get the latest chart with broker recommendations from Zacks Investment Research. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

CMRX: Chimerix, Inc. Detailed Estimate. Get the latest Detailed Estimate from Zacks Investment Research.